[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"app-context":3,"blog-9-of-the-fastest-growing-biotech-stocks-under-10-billion-ZH":150},{"languages":4,"categories":41,"products":125,"competitors":149},[5,9,13,17,21,25,29,33,37],{"name":6,"code":7,"id":8},"English","EN","TGFuZ3VhZ2U6ZW4=",{"name":10,"code":11,"id":12},"Español","ES","TGFuZ3VhZ2U6ZXM=",{"name":14,"code":15,"id":16},"Português","PT","TGFuZ3VhZ2U6cHQ=",{"name":18,"code":19,"id":20},"日本語","JA","TGFuZ3VhZ2U6amE=",{"name":22,"code":23,"id":24},"한국어","KO","TGFuZ3VhZ2U6a28=",{"name":26,"code":27,"id":28},"Deutsch","DE","TGFuZ3VhZ2U6ZGU=",{"name":30,"code":31,"id":32},"Italiano","IT","TGFuZ3VhZ2U6aXQ=",{"name":34,"code":35,"id":36},"Français","FR","TGFuZ3VhZ2U6ZnI=",{"name":38,"code":39,"id":40},"中文 (中国)","ZH","TGFuZ3VhZ2U6emg=",[42,73,104],{"icon":43,"slug":44,"title":45,"description":46,"featuredLinks":47},"mingcute:stock-line","stock-market-basics","Stock Market Basics","\u003Cp>Beginners' guides and practical tips for understanding stock market investing.\u003C\u002Fp>\n",[48,53,58,63,68],{"url":49,"title":50,"description":51,"ogImage":52},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-makes-stocks-go-up-and-down","What Makes Stocks Go Up and Down | TIKR.com","Understanding what makes stock prices go up and down can help investors better navigate investing. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-makes-stocks-go-up-and-down-banner\u002FWhat-makes-stocks-go-up-and-down-banner.jpg?_i=AA",{"url":54,"title":55,"description":56,"ogImage":57},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fdividend-yield-meaning-formula-example","Dividend Yield: Meaning, Formula, Example | Tikr.com Blog | TIKR.com","The dividend yield is a key metric for investors looking to gauge the income potential of their investments. It measures how much a company pays out in","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FDividend-yield\u002FDividend-yield.png?_i=AA",{"url":59,"title":60,"description":61,"ogImage":62},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fmarket-capitalization-definition-formula-and-why-it-matters","Market Capitalization: Definition, Formula, and Why It Matters | TIKR.com","Long-term investors often look at various valuation metrics when deciding whether to invest in a particular company. One helpful metric to evaluate is","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters\u002FMarket-Capitalization-Definition-Formula-and-Why-It-Matters.png?_i=AA",{"url":64,"title":65,"description":66,"ogImage":67},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fearnings-per-share-definition-formula-and-why-eps-matters","Earnings Per Share: Definition, Formula, and Why EPS Matters | TIKR.com","Earnings Per Share (EPS) represents the portion of a company's net earnings allocated to each share. Click to learn more!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEPS-Defiinition-formula-and-why-EPS-matters-1\u002FEPS-Defiinition-formula-and-why-EPS-matters-1.png?_i=AA",{"url":69,"title":70,"description":71,"ogImage":72},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-stock-price-target","What Is a Stock Price Target? | TIKR.com","A price target is a stock's estimated future price. It can help investors quickly find undervalued stocks. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-Stock-Price-Target-2\u002FWhat-is-a-Stock-Price-Target-2.png?_i=AA",{"icon":74,"slug":75,"title":76,"description":77,"featuredLinks":78},"material-symbols:analytics-outline","fundamental-analysis","Fundamental Analysis","\u003Cp>In-depth resources and financial metrics to help you evaluate companies like a pro.\u003C\u002Fp>\n",[79,84,89,94,99],{"url":80,"title":81,"description":82,"ogImage":83},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fshare-repurchase-why-do-companies-buy-back-their-stock","Share Repurchase: Why Do Companies Buy Back Their Stock? | TIKR.com","Share repurchases, or share buybacks, have gained popularity in the last two decades. According to a report from Goldman Sachs, stock buybacks initiated","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e\u002FTIKR-BLOG-COVER-PHOTOS-3_544a7f4e.png?_i=AA",{"url":85,"title":86,"description":87,"ogImage":88},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-invested-capital","What Is a Good Return on Invested Capital? | TIKR.com","Learning about Return on Invested Capital (ROIC) can help investors spot highly profitable stocks that can drive long-term returns. Learn more now!","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-Invested-capital\u002FWhat-is-a-good-return-on-Invested-capital.png?_i=AA",{"url":90,"title":91,"description":92,"ogImage":93},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-return-on-equity-ratio","What is a Good Return on Equity Ratio | Tikr.com Blog | TIKR.com","Return on Equity (ROE) is a financial ratio that reflects a company's profitability in relation to the equity invested by shareholders. It basically","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-return-on-equity-ratio-1\u002FWhat-is-a-good-return-on-equity-ratio-1.jpg?_i=AA",{"url":95,"title":96,"description":97,"ogImage":98},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-a-good-p-e-ratio","What Is a Good P\u002FE Ratio? | TIKR.com","Financial analysts and investors look at various metrics before deciding whether a stock is a buy. One of the metrics is the price-to-earnings ratio (P\u002FE","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-a-good-PE-ratio-1\u002FWhat-is-a-good-PE-ratio-1.jpg?_i=AA",{"url":100,"title":101,"description":102,"ogImage":103},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Ftop-6-metrics-for-investing-in-reits","Top 6 Metrics for Investing in REITs | TIKR.com","Real estate has been one of the greatest asset classes for wealth creation in history, and investing in Real Estate Investment Trusts (REITs) can allow","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FGroup-10\u002FGroup-10.png?_i=AA",{"icon":105,"slug":106,"title":107,"description":108,"featuredLinks":109},"hugeicons:investigation","investing-lingo","Investing Lingo","\u003Cp>A comprehensive glossary of investing terms and jargon so you can speak the language of the markets confidently.\u003C\u002Fp>\n",[110,115,120],{"url":111,"title":112,"description":113,"ogImage":114},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fenterprise-value-definition-and-calculation","Enterprise Value: Definition and Calculation | Tikr.com Blog | TIKR.com","Enterprise value (EV) is a financial metric that offers a comprehensive snapshot of a company's total value. Unlike market capitalization which solely","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEnterprise-Value-Definition-and-Calculation_37576e40\u002FEnterprise-Value-Definition-and-Calculation_37576e40.png?_i=AA",{"url":116,"title":117,"description":118,"ogImage":119},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Febitda-definition-formula-how-to-use-it","EBITDA: Definition, Formula, How to Use It | TIKR.com","EBITDA stands for earnings before interest, taxes, depreciation and amortization. It's a financial metric commonly used to evaluate a company's financial","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FEBITDA-Definition-Formula-How-to-Use-It\u002FEBITDA-Definition-Formula-How-to-Use-It.png?_i=AA",{"url":121,"title":122,"description":123,"ogImage":124},"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Fwhat-is-the-free-cash-flow-formula-and-why-does-it-matter","What is the Free Cash Flow Formula and Why Does It Matter | TIKR.com","Free cash flow, or FCF, is the cash a company generates after it accounts for outflows required to maintain business operations and support capital","https:\u002F\u002Fwww.tikr.com\u002Fimages\u002FWhat-is-the-free-cash-flow-formula\u002FWhat-is-the-free-cash-flow-formula.png?_i=AA",[126,130,134,137,141,145],{"slug":127,"modified":128,"title":129},"valuation-model-builder","2025-07-03T00:18:53","Value Stocks Quickly and Accurately",{"slug":131,"modified":132,"title":133},"stock-portfolio-tracking","2024-12-02T22:21:28","Monitor Your Portfolio",{"slug":75,"modified":135,"title":136},"2025-01-21T22:10:52","Instantly Analyze Companies with In-Depth Metrics",{"slug":138,"modified":139,"title":140},"stock-screener","2024-12-02T22:13:31","Find the Best Stocks to Buy",{"slug":142,"modified":143,"title":144},"investor-stock-portfolio","2025-01-21T22:02:56","Follow Investment Moves of Top Investors",{"slug":146,"modified":147,"title":148},"analyze-stocks","2025-07-23T16:04:24","Analyze Stocks",[],{"post":151,"seo":186,"relatedPosts":192,"suggestedPosts":193},{"id":152,"title":153,"date":154,"modified":155,"excerpt":156,"content":157,"wordCount":158,"lang":159,"uri":160,"slug":161,"cloudinaryAssetId":162,"featuredImageOriginalUrl":163,"featuredImageMetadata":164,"author":166,"editor":172,"categories":177,"relatedPosts":183,"seo":184},53835,"百亿美元以下增长最快的 9 只生物技术股","2025-09-14T15:35:00","2025-09-13T13:21:44","\u003Cp>以下是价值 100 亿美元以下增长最快的 9 只生物技术股，它们拥有强大的保险公司支持和不断增长的国际需求。探索塑造未来医学的公司的高潜力投资机会。\u003C\u002Fp>\n","\n\u003Cp>生物技术行业仍然是创新的温床，100 亿美元以下的公司因其突破性疗法和快速增长潜力而备受关注。 \u003C\u002Fp>\n\n\n\n\u003Cp>这些增长最快的生物技术股不仅在推进尖端疗法，而且还得到了保险公司的大力支持和国际关注度的不断扩大，这标志着强劲的收入来源和长期的可扩展性。\u003Cbr>\u003Cbr>以下是市值低于 100 亿美元、增长最快的 9 只生物技术股，它们都拥有强大的保险公司支持和不断增长的国际需求。\u003C\u002Fp>\n\n\n\n\u003Cfigure class=\"wp-block-table\">\u003Ctable class=\"has-fixed-layout\">\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>公司名称（股票代码）\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>\u003Cstrong>分析师预测\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>\u003Cstrong>市盈率\u003C\u002Fstrong>\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Arcutis Biotherapeutics (ARQT)\u003C\u002Ftd>\u003Ctd>26.4%\u003C\u002Ftd>\u003Ctd>-107.41\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>塔尔苏斯制药公司\u003Cstrong> ( \u003C\u002Fstrong>TARS)\u003C\u002Ftd>\u003Ctd>54%\u003C\u002Ftd>\u003Ctd>-275.90\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Crinetics 制药公司 (CRNX)\u003C\u002Ftd>\u003Ctd>124.4%\u003C\u002Ftd>\u003Ctd>-5.85\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Palvella Therapeutics (PVLA)\u003C\u002Ftd>\u003Ctd>22.3%\u003C\u002Ftd>\u003Ctd>-16.71\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>IO 生物技术公司 (IOBT)\u003C\u002Ftd>\u003Ctd>408.5%\u003C\u002Ftd>\u003Ctd>-1.81\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Spero Therapeutics (SPRO)\u003C\u002Ftd>\u003Ctd>168.8%\u003C\u002Ftd>\u003Ctd>-1.11\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>维尔生物技术公司 (VIR)\u003C\u002Ftd>\u003Ctd>302.4%\u003C\u002Ftd>\u003Ctd>-1.49\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>Tiziana 生命科学有限公司 (TLSA)\u003C\u002Ftd>\u003Ctd>314.4%\u003C\u002Ftd>\u003Ctd>-10.72\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>桥生物制药公司\u003Cstrong> ( \u003C\u002Fstrong>BBIO)\u003C\u002Ftd>\u003Ctd>24.3%\u003C\u002Ftd>\u003Ctd>-21.29\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Ffigure>\n\n\n\n\u003Cp>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fa>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Cem>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog-compoundersreport\">解锁我们的免费报告：根据华尔街的增长预期，5 家价值被低估的复合型企业具有上升空间，可带来跑赢大市的回报（注册 TIKR，免费） >>>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fem>\u003C\u002Fp>\n\n\n\n\u003Cp>以下3只生物技术股因其快速的\u003Ca href=\"https:\u002F\u002Fwww.tikr.com\u002Fblog\u002Frevenue-growth-why-its-important-and-key-drivers\">收入增长\u003C\u002Fa>、强大的保险公司覆盖范围和不断扩大的国际影响力而脱颖而出，成为极具潜力的机会。\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-arcutis-biotherapeutics-arqt\">Arcutis Biotherapeutics\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=549019944&tid=650259531&ref=tikrblog\">(ARQT\u003C\u002Fa>)\u003C\u002Fh2>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-full is-resized\">\u003Cimg width=\"936\" height=\"589\" data-public-id=\"\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_936,h_589,c_scale\u002Ff_webp,q_auto\u002Fv1757769456\u002Fimages\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM.?_i=AA\" alt=\"\" class=\"wp-post-53835 wp-image-67669\" style=\"width:800px\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1757769456\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1757769456\u002Fimages\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM.?_i=AA 936w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_189,c_scale\u002Ff_webp,q_auto\u002Fv1757769456\u002Fimages\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM.?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_483,c_scale\u002Ff_webp,q_auto\u002Fv1757769456\u002Fimages\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM\u002F17-29-Arcutis-Biotherapeutics-Inc-ARQT-TIKR-Terminal-09-13-2025_09_14_AM.?_i=AA 768w\" sizes=\"auto, (max-width: 936px) 100vw, 936px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Arcutis Biotherapeutics\u003Cstrong> \u003C\u002Fstrong>目标价 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Arcutis Biotherapeutics \u003C\u002Fstrong>在市值低于 100 亿美元的生物技术公司中脱颖而出，其增长率远远超过许多同行。该公司正通过解决牛皮癣、湿疹和特应性皮炎等常见但服务不足的疾病，在皮肤科领域建立领导地位。与许多处于临床阶段的生物技术公司不同，Arcutis 已经取得了商业上的成功，2025 年第二季度的收入同比增长了 164%。这一增长反映了医生和患者的强烈需求，彰显了公司将创新科学转化为可扩展商业模式的能力。\u003C\u002Fp>\n\n\n\n\u003Cp>对投资者而言，Arcutis 的吸引力在于其严格专注于未满足需求较高的领域，这不仅加快了开发进度，还提供了有意义的定价权和市场独占权。公司的高价疗法和高效的商业化战略推动了收入的强劲增长，而合作伙伴关系和许可协议则扩大了公司的市场占有率，降低了执行风险。目前，Arcutis 的市值仍远低于 100 亿美元，它代表了一种罕见的快速顶线增长、运营纪律和明确治疗重点的融合。这使该公司成为最引人注目的高增长生物技术公司之一，具有巨大的长期上涨潜力。\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">使用 TIKR 的新估值模型在 30 秒内对任何股票进行估值（免费） >>>\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-tarsus-pharmaceuticals-nbsp-tars\">\u003Cstrong>塔尔萨斯制药公司 \u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=650383665&tid=690099073&ref=tikrblog\">(TARS\u003C\u002Fa>)\u003C\u002Fh2>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-full is-resized\">\u003Cimg width=\"939\" height=\"585\" data-public-id=\"images\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570.webp\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_939,h_585,c_scale\u002Ff_webp,q_auto\u002Fv1757769513\u002Fimages\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570.webp?_i=AA\" alt=\"\" class=\"wp-post-53835 wp-image-67678 wp-image-67679\" style=\"width:800px\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1757769513\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1757769513\u002Fimages\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570.webp?_i=AA 939w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_187,c_scale\u002Ff_webp,q_auto\u002Fv1757769513\u002Fimages\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570.webp?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_478,c_scale\u002Ff_webp,q_auto\u002Fv1757769513\u002Fimages\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570\u002F49-36-Tarsus-Pharmaceuticals-Inc-TARS-TIKR-Terminal-09-13-2025_09_15_AM_6767924570.webp?_i=AA 768w\" sizes=\"auto, (max-width: 939px) 100vw, 939px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">塔尔萨斯制药公司目标价 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Tarsus Pharmaceuticals\u003C\u002Fstrong>在眼科和传染病治疗领域占据了一席之地，主要针对治疗方案有限的病症。公司的战略重点是服务不足的眼科市场，这使公司的疗法获得了令人印象深刻的采用率。2025 年第二季度的销售额同比激增 152%，达到 1.027 亿美元，彰显了强劲的收入增长和运营可扩展性。 \u003C\u002Fp>\n\n\n\n\u003Cp>Tarsus 专注于尚未满足大量需求的疾病，因此能获得有利的定价，并建立起忠实的患者基础。公司的后期产品线进一步促进了公司的增长，其中包括前景广阔的候选药物，扩大了公司的可解决市场。精确制剂技术和靶向给药系统为 Tarsus 带来了竞争优势，既提高了疗效，又改善了患者预后。 \u003C\u002Fp>\n\n\n\n\u003Cp>对创新的专注，加上强大的商业执行力，使 Tarsus 成为生物技术领域快速成长的企业。Tarsus 的市值不到 100 亿美元，是高增长生物技术公司的理想代表：公司利用创新打入专业市场，同时迅速扩大收入。其严谨的执行力，加上不断扩大的产品线，确保了它在以眼科为重点的生物技术领域仍然是一个引人注目的增长故事。\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cem>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">今天就用 TIKR 查找我们比 Tarsus Pharmaceuticals 更看好的股票（免费） >>>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-crinetics-pharmaceuticals-nbsp-crnx\">\u003Cstrong>克里尼特制药公司 \u003C\u002Fstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fstock\u002Fabout?cid=280584191&tid=571929238&ref=tikrblog\">(CRNX\u003C\u002Fa>)\u003C\u002Fh2>\n\n\n\u003Cdiv class=\"wp-block-image\">\n\u003Cfigure class=\"aligncenter size-full is-resized\">\u003Cimg width=\"936\" height=\"591\" data-public-id=\"\" loading=\"lazy\" decoding=\"async\" src=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_936,h_591,c_scale\u002Ff_webp,q_auto\u002Fv1757769711\u002Fimages\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb.?_i=AA\" alt=\"\" class=\"wp-post-53835 wp-image-67687\" style=\"width:800px\" data-format=\"webp\" data-transformations=\"f_webp,q_auto\" data-version=\"1757769711\" data-seo=\"1\" srcset=\"https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1757769711\u002Fimages\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb.?_i=AA 936w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_300,h_189,c_scale\u002Ff_webp,q_auto\u002Fv1757769711\u002Fimages\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb.?_i=AA 300w, https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Fw_768,h_485,c_scale\u002Ff_webp,q_auto\u002Fv1757769711\u002Fimages\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb\u002F34-00-Crinetics-Pharmaceuticals-Inc-CRNX-TIKR-Terminal-09-13-2025_09_16_AM_67687888cb.?_i=AA 768w\" sizes=\"auto, (max-width: 936px) 100vw, 936px\" \u002F>\u003Cfigcaption class=\"wp-element-caption\">Crinetics 制药公司目标价 (\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">TIKR\u003C\u002Fa>\u003C\u002Fstrong>)\u003C\u002Ffigcaption>\u003C\u002Ffigure>\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Crinetics Pharmaceuticals\u003C\u002Fstrong>因其专注于罕见内分泌和代谢疾病而脱颖而出，这是一个既有大量未满足医疗需求又有强大市场潜力的生物技术领域。该公司已成功推进了多个临床阶段项目，包括其治疗肢端肥大症的主要候选药物 paltusotine，该药物已获得美国食品及药物管理局（FDA）的新药申请审查许可。这一进展表明，Crinetics 有能力将科学创新有效地转化为具有商业前景的疗法。\u003C\u002Fp>\n\n\n\n\u003Cp>Crinetics 尤为引人注目的是其运营纪律和资本效率。公司在不过度消耗资源的情况下，推进了多样化的产品线。公司对罕见病的关注也加速了监管途径，使 Crinetics 有可能比传统的大市值生物技术公司更快地将疗法推向市场。\u003C\u002Fp>\n\n\n\n\u003Cp>凭借即将公布的临床数据和潜在的市场批准所带来的强劲的近期催化剂，Crinetics 成为一家快速发展的生物技术公司的典范，其市值不到 100 亿美元。它将创新、高影响力的科学、审慎的财务和对罕见病的战略关注结合在一起，确保了它在快速发展的生物技术行业中仍然是一个突出的投资机会。\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cem>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">\u003Cstrong>Crinetics Pharmaceuticals\u003C\u002Fstrong>等价值型股票，TIKR 更快 >>>\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-wall-street-analysts-are-bullish-on-these-5-undervalued-compounders-with-market-beating-potential\">\u003Cstrong>华尔街分析师看好这 5 家被低估的复合药企，它们具有战胜市场的潜力\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>TIKR 刚刚发布了一份新的免费报告，介绍了 5 家\u003Cstrong>价值\u003C\u002Fstrong>似乎\u003Cstrong>被低估的\u003C\u002Fstrong>复合药企，它们在过去曾\u003Cstrong>战胜过市场 \u003C\u002Fstrong>，而且根据分析师的估计，它们在 1-5 年的时间里可能继续\u003Cstrong>跑\u003C\u002Fstrong> \u003Cstrong>赢大盘 \u003C\u002Fstrong>。\u003C\u002Fp>\n\n\n\n\u003Cp>在这份报告中，你将了解到 5 家优质企业的详细情况，这些企业拥有\u003C\u002Fp>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>强劲的收入增长和持久的竞争优势\u003C\u002Fli>\n\n\n\n\u003Cli>基于远期收益和预期收益增长的诱人估值\u003C\u002Fli>\n\n\n\n\u003Cli>分析师预测和 TIKR 估值模型支持的长期上涨潜力\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Cp>这些都是可以带来巨大长期回报的股票，尤其是如果您在它们仍以折扣价交易时抓住它们。\u003C\u002Fp>\n\n\n\n\u003Cp>无论您是长期投资者，还是只想寻找以低于公允价值交易的优秀企业，本报告都将帮助您锁定高溢价机会。\u003C\u002Fp>\n\n\n\n\u003Cp>\u003Cstrong>\u003Cem>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog-compoundersreport\">单击此处注册 TIKR，免费获取我们关于 5 家价值被低估的复合型企业的完整报告。\u003C\u002Fa>\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-looking-for-new-opportunities\">\u003Cstrong>寻找新机会？\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cul class=\"wp-block-list\">\n\u003Cli>查看\u003Cstrong> \u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">亿万富翁投资者正在购买\u003C\u002Fa> \u003C\u002Fstrong>哪些股票\u003Cstrong> ，让 \u003C\u002Fstrong>您跟随聪明资金的步伐。\u003C\u002Fli>\n\n\n\n\u003Cli>\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">分析股票只需 5 分钟\u003C\u002Fa>\u003C\u002Fstrong>使用 TIKR 的一体化易用平台。\u003C\u002Fli>\n\n\n\n\u003Cli>您推翻的岩石越多......您发现的机会就越多。\u003Cstrong>\u003Ca href=\"https:\u002F\u002Fapp.tikr.com\u002Fregister?ref=tikrblog\">使用 TIKR 搜索 100K+ 全球股票、全球顶级投资者持有的股票等。\u003C\u002Fa>\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\n\n\u003Ch2 class=\"wp-block-heading\" id=\"h-disclaimer\">\u003Cstrong>免责声明：\u003C\u002Fstrong>\u003C\u002Fh2>\n\n\n\n\u003Cp>\u003Cem>请注意，TIKR 上的文章无意作为 TIKR 或我们内容团队的投资或财务建议，也不是买卖任何股票的建议。我们根据 TIKR 终端的投资数据和分析师的估计创建内容。我们的分析可能不包括最近的公司新闻或重要更新。\u003C\u002Fem>\u003Cem>TIKR 不持有所提及的任何股票。\u003C\u002Fem>\u003Cem>感谢您的阅读，祝您投资愉快！\u003C\u002Fem>\u003C\u002Fp>\n",1052,"zh","\u002Fblog\u002F9-of-the-fastest-growing-biotech-stocks-under-10-billion","9-of-the-fastest-growing-biotech-stocks-under-10-billion","images\u002FFEATURED-IMAGE-MAKER-1_566292b694\u002FFEATURED-IMAGE-MAKER-1_566292b694","https:\u002F\u002Fres.cloudinary.com\u002Ftikr\u002Fimages\u002Ff_webp,q_auto\u002Fv1757106908\u002Fimages\u002FFEATURED-IMAGE-MAKER-1_566292b694\u002FFEATURED-IMAGE-MAKER-1_566292b694.?_i=AA",{"altText":153,"imageCredit":165},"Canva",{"name":167,"slug":168,"role":169,"roleTitle":170,"biography":170,"avatar":170,"socialMediaLinks":171},"Cate Ciplak","catetikr","author","",[],{"name":173,"slug":174,"role":175,"roleTitle":170,"biography":170,"avatar":170,"socialMediaLinks":176},"Thomas Richmond","thomastikr","editor",[],[178],{"name":179,"slug":180,"uri":181,"description":170,"postsCount":182},"Stock Reviews","reviews","\u002Fblog\u002Fcategory\u002Freviews",0,[],{"title":153,"metaDesc":185,"opengraphDescription":185,"twitterTitle":153,"twitterDescription":185},"以下是价值 100 亿美元以下增长最快的 9 只生物技术股，它们拥有强大的保险公司支持和不断增长的国际需求。探索塑造未来医学的公司的高潜力投资机会。",{"title":153,"description":185,"twitterTitle":153,"twitterDescription":185,"author":167,"articlePublisher":187,"articlePublishedTime":154,"articleModifiedTime":155,"twitterLabel1":188,"twitterData1":189,"ogTitle":153,"ogDescription":185,"ogUrl":160,"ogImage":163,"ogImageWidth":190,"ogImageHeight":191,"ogImageSecureUrl":163,"ogImageAlt":153,"twitterImage":163},"TIKR.com","预计阅读时间","2 minutes",1200,630,[],[]]